Freestone Grove Partners LP Axsome Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 2,494 shares of AXSM stock, worth $348,386. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,494Holding current value
$348,386% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AXSM
# of Institutions
420Shares Held
36.9MCall Options Held
752KPut Options Held
567K-
Vanguard Group Inc Valley Forge, PA4.18MShares$584 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...